George Yancopoulos, President and Chief Scientific at REGENERON PHARMACEUTICALS, INC. (REGN), sold 160,000 shares at $537.61 ($86.2M) on 2021-06-21, disclosed to the SEC on 2021-06-23.
Open-market sale of $86.2M REGN by President and Chief Scientific. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $532.89 | 738 | $393K | 0.5% |
| 2 | $532.89 | 738 | $393K | 0.5% |
| 3 | $533.66 | 7,494 | $4.0M | 4.6% |
| 4 | $533.66 | 7,494 | $4.0M | 4.6% |
| 5 | $534.48 | 8,236 | $4.4M | 5.1% |
| 6 | $534.48 | 8,236 |
| $4.4M |
| 5.1% |
| 7 | $535.63 | 4,154 | $2.2M | 2.6% |
| 8 | $535.63 | 4,154 | $2.2M | 2.6% |
| 9 | $536.37 | 3,768 | $2.0M | 2.3% |
| 10 | $536.37 | 3,768 | $2.0M | 2.3% |
| 11 | $537.61 | 6,636 | $3.6M | 4.1% |
| 12 | $537.61 | 6,636 | $3.6M | 4.1% |
| 13 | $538.54 | 4,868 | $2.6M | 3.0% |
| 14 | $538.54 | 4,868 | $2.6M | 3.0% |
| 15 | $539.66 | 3,306 | $1.8M | 2.1% |
| 16 | $539.66 | 3,306 | $1.8M | 2.1% |
| 17 | $540.61 | 8,099 | $4.4M | 5.1% |
| 18 | $540.61 | 8,099 | $4.4M | 5.1% |
| 19 | $541.44 | 19,911 | $10.8M | 12.5% |
| 20 | $541.44 | 19,911 | $10.8M | 12.5% |
| 21 | $542.43 | 10,514 | $5.7M | 6.6% |
| 22 | $542.43 | 10,514 | $5.7M | 6.6% |
| 23 | $543.13 | 2,276 | $1.2M | 1.4% |
| 24 | $543.13 | 2,276 | $1.2M | 1.4% |
| Total | $538.90 avg | 160,000 | $86.2M | 100% |
| Filing → |
| REGN | SELL | 2024-01-04 | $15.2M | — | Filing → |
| REGN | SELL | 2023-03-27 | $5.0M | — | Filing → |
| REGN | SELL | 2023-02-08 | $21.1M | — | Filing → |